Ask Orbit
Commercial Intelligence
Commercial Intelligence/Commercial Flow

Commercial Flow

End-to-end view of product movement from sell-in through stock, sell-out and customer demand.

1 – 30 Jun 2026·All Divisions·All Regions·All Categories·All Wholesalers
Demo Data
Orbit Commercial-Flow Briefing
Updated 14 min ago

Commercial flow is healthy for most of the portfolio, but three bottlenecks require attention. Cardiaxol demand is rising faster than replenishment, Respireze stock is accumulating at Wholesaler A, and R2.4m of value is currently blocked in backorders. Western Cape shows the strongest sell-through, while Gauteng North shows weak sell-out despite above-plan sell-in.

Primary Sales
R267.2m
+5.9% vs prev period
Wholesaler Stock
R46.8m
Accumulating
+3.1% vs prev period
Secondary Sales
R281.5m
+2.8% vs prev period
Sell-Through Rate
82.4%
Slowing
-1.8 pp vs prev period
Backorder Value
R6.7m
Rising
+R0.6m vs prev period
Flow Efficiency
78%
Below
-3 pp vs prev period
End-to-end commercial flow
Sell-in → stock → sell-out → demand → unfulfilled · click a stage to investigate
Zydus Sell-In
R267.2m
8.7m u
+5.9%93% attn
Healthy
Wholesaler Inventory
R46.8m
1.5 mo cov
+3.1%9 wh
Accumulating
Secondary Sell-Out
R281.5m
9.2m u
+2.8%82.4% sell-thru
Constrained
Customer Demand
R291.4m
4,286 cx
+4.2%+3.4% cust
Healthy
Backorders / Unfulfilled
R6.7m
184.6k u
+12.4%R2.1m ready
Blocked
Healthy Accumulating / slow Constrained / blocked
Product flow matrix
Primary → stock → secondary · flow status per product
ProductPrimaryStockSecondarySell-thruBOStatusImpact
Cardiaxol 20mgR18.6mR3.4mR21.2m92%R2.1mconstrainedR2.4m at risk
Cardiaxol 40mgR9.7mR1.8mR10.4m88%R0.7mreplenishR0.9m at risk
Respireze InhalerR12.4mR9.6mR9.1m62%R1.6maccumulatingR1.4m tied up
Gastraven 20mgR7.2mR1.6mR7.6m91%R0.5mhealthyStable
Neurospen 500R3.4mR2.9mR2.9m58%R0.3mdeclining-11.8% MoM
Pulmavent DPIR4.1mR0.9mR3.6m84%R0.9mconstrainedR0.6m at risk
Metaform 850R2.6mR1.4mR2.4m71%—accumulatingSlow-moving
Bottleneck ranking
Ranked by commercial impact
Cardiaxol 20mg
Wholesaler Inventory · 9 days
R2.4m
Expedite inbound; reallocate to WC
Respireze Inhaler @ Wholesaler A
Sell-Through · 38 days
R1.4m
Redistribute 600u to Wholesaler C
Backorders (Top 3 SKUs)
Unfulfilled Demand · 18 days avg
R2.4m
Partial fulfil ready value R2.1m
Gauteng North
Sell-Out · 3 periods
R1.8m
Rep coverage + KAM outreach
Pulmavent DPI
Wholesaler Inventory · 12 days
R0.6m
Escalate to Supply Planning
Primary vs Secondary growth
Sell-in vs sell-out momentum
Top-right: balanced growth · Top-left: demand ahead · Bottom-right: sell-in ahead · Bottom-left: decline
Stock cover vs sell-through
Identify slow, excess, healthy & fast-risk
Risks & opportunities
Prioritised for this period
Risks
Primary ahead of sell-out at Wholesaler A+18 days
Cardiaxol demand constrained by stockR2.4m
R2.4m blocked in ageing backordersR2.4m
Weak flow efficiency in Gauteng North-14 pp
Opportunities
Redistribute excess stock across wholesalers+R1.1m
Increase replenishment on high-demand SKUs+R0.9m
Expand distribution where sell-through strong+R0.7m
Reduce primary orders on slow-moving products-R0.5m tied
Commercial flow detail
Full flow view per product & wholesaler with recommended action
ProductBrandWholesalerPrimaryStockSecondarySell-thruCoverBOFlow eff.StatusImpactAction
Cardiaxol 20mgCardiaxolWholesaler CR18.6mR3.4mR21.2m92%9dR2.1m74%constrainedR2.4m at riskExpedite + reallocate
Respireze InhalerRespirezeWholesaler AR12.4mR9.6mR9.1m62%74dR1.6m58%accumulatingR1.4m tiedRedistribute 600u to WC
Cardiaxol 40mgCardiaxolRegional Health SupplyR9.7mR1.8mR10.4m88%11dR0.7m79%replenishR0.9m at riskConfirm ETA
Gastraven 20mgGastravenWholesaler BR7.2mR1.6mR7.6m91%27dR0.5m88%healthyStableSustain
Neurospen 500NeurospenWholesaler AR3.4mR2.9mR2.9m58%62dR0.3m61%declining-11.8% MoMReduce inbound
Pulmavent DPIPulmaventWholesaler AR4.1mR0.9mR3.6m84%12dR0.9m71%constrainedR0.6m at riskEscalate supply
Metaform 850MetaformWholesaler BR2.6mR1.4mR2.4m71%48d—74%accumulatingSlow-movingSlow replenishment
Primary Sales
Inspect sell-in drivers
Inventory & Stock Health
Investigate stock position
Backorders & Supply Risk
Unblock revenue